Drugs / Nogapendekin Alfa
Nogapendekin Alfa
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05096663 | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nogapendekin Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05096663 ↗ |
| Known as | IL-15N72D | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297690 ↗ |
| Known as | Nogapendekina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297690 ↗ |
| Known as | Nogapendekine alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297690 ↗ |
| Action | Activate | “N-803 (ALT-803) may activate natural killer cells” NCT05096663 ↗ |
| Modality | Protein / enzyme biologic | “Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC” NCT05096663 ↗ |
| Route | Subcutaneous | “Given SC” NCT05096663 ↗ |